CARsgen Therapeutics Holdings (HKSE:02171) Construction In Progress: HK$3.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02171 CARsgen Therapeutics Holdings Ltd HKSE:02171
32 GF Score
Price HK$14.90
! 3 Warning Signs
View Full Analysis

What is CARsgen Therapeutics Holdings Construction In Progress?

CARsgen Therapeutics Holdings HKSE:02171 +1.36% 32 Construction In Progress is HK$3.2 Mil as of Dec. 2025. GuruFocus rates HKSE:02171 with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

CARsgen Therapeutics Holdings's quarterly construction in progress declined from Dec. 2024 (HK$14.3 Mil) to Jun. 2025 (HK$0.0 Mil) but then increased from Jun. 2025 (HK$0.0 Mil) to Dec. 2025 (HK$3.2 Mil).

CARsgen Therapeutics Holdings's annual construction in progress increased from Dec. 2023 (HK$3.8 Mil) to Dec. 2024 (HK$14.3 Mil) but then declined from Dec. 2024 (HK$14.3 Mil) to Dec. 2025 (HK$3.2 Mil).

CARsgen Therapeutics Holdings Construction In Progress Historical Data

* Premium members only.

The historical data trend for CARsgen Therapeutics Holdings's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARsgen Therapeutics Holdings Construction In Progress Chart

CARsgen Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial 192.85 15.92 3.77 14.35 3.21

CARsgen Therapeutics Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.77 0.00 14.35 0.00 3.21
HKSE:02171
32GF Score
CARsgen Therapeutics Holdings Ltd HKSE:02171
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CARsgen Therapeutics Holdings Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of HK$3.2 Mil mean?
CARsgen Therapeutics Holdings (HKSE:02171) has a Construction In Progress of HK$3.2 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on CARsgen Therapeutics Holdings and its competitors.
Is CARsgen Therapeutics Holdings' Construction In Progress too high?
CARsgen Therapeutics Holdings' current Construction In Progress is HK$3.2 Mil. Overall, CARsgen Therapeutics Holdings has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does CARsgen Therapeutics Holdings' Construction In Progress compare to VRTX and REGN?
CARsgen Therapeutics Holdings' Construction In Progress of HK$3.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on CARsgen Therapeutics Holdings and its competitors. CARsgen Therapeutics Holdings's current Construction In Progress is HK$3.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARsgen Therapeutics Holdings stock overvalued right now?
CARsgen Therapeutics Holdings (HKSE:02171) has a current Construction In Progress of HK$3.2 Mil. The current Construction In Progress is HK$3.2 Mil. CARsgen Therapeutics Holdings' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For CARsgen Therapeutics Holdings (HKSE:02171), the current Construction In Progress is HK$3.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CARsgen Therapeutics Holdings Business Description

Other Exchanges CRTHF:USA
Address No. 466 Yindu Road, Building 2, 1st Floor, Xuhui District, Shanghai, CHN
CARsgen Therapeutics Holdings Ltd is a clinical-stage biopharmaceutical company discovering, researching, and developing cell therapies in the People's Republic of China and the United States of America. During the year, a majority of the Group's revenue was derived from one customer located in the Chinese mainland.
32GF Score

Get the complete analysis for HKSE:02171

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$14.90
Price